Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.43 |
| ▸ | CDK2 | P24941 | 5/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305316 | 0.84 | CHEK1 (0.46) | CHEK1CCNA2CDK2CCNA1GSK3B | |
| SCHEMBL3303802 | 0.82 | HTR2A (0.43) | CHEK1CCNA2CDK2CCNA1JAK2 | |
| SCHEMBL3304440 | 0.81 | PTK2 (0.39) | CHEK1CCNA2CDK2CCNA1JAK2 | |
| SCHEMBL2144921 | 0.77 | CHEK1 (0.49) | CHEK1CCNA2CDK2CCNA1ADORA2A | |
| SCHEMBL3297635 | 0.77 | IDH2 (0.47) | CDK2JAK2PRKCZPRKD2 | |
| SCHEMBL3303916 | 0.77 | IDH2 (0.47) | CDK2JAK2PRKCZPRKD2 | |
| SCHEMBL2144859 | 0.70 | CHEK1 (0.40) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL3309511 | 0.66 | IDH2 (0.50) | CHEK1CDK2JAK2JAK3PRKCZ | |
| SCHEMBL3304385 | 0.66 | IDH2 (0.50) | CHEK1CDK2JAK2JAK3PRKCZ | |
| SCHEMBL3302493 | 0.66 | IDH2 (0.50) | CHEK1CDK2JAK2JAK3PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CHEK1 44/4885CCNA2 587/4885CDK2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.